The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation.

Laura FanningJenni IlomäkiJ Simon BellPēteris Dārziņš

Published in: European journal of clinical pharmacology (2017)

The apixaban and dabigatran trials may be the most representative of hospitalized patients with AF. The DOAC trial results can readily be extrapolated to, and guide prescribing for, at least two thirds of patients discharged from a large metropolitan health service in Australia.

Keyphrases

atrial fibrillation
clinical trial
end stage renal disease
venous thromboembolism
chronic kidney disease
ejection fraction
newly diagnosed
direct oral anticoagulants
phase ii
phase iii
peritoneal dialysis
prognostic factors
study protocol
cross sectional
patient reported outcomes
open label
patient reported